CA great comments and I share your views -- I am hoping they have nailed down these agreements already - but having been in this stock for over many years now I have observed that some of these catalysts and milestones which the company has targeted, usually have slipped due to dependencies which were outside their control, internal resource constraints, etc. After the funding round they were able to hire more resources and begin to gain traction in some areas - they have even acknowledged on prior calls that they have kept the Hemodefend design and manufacturing activities going on behind the scenes which is optimistic and add's weight to your point. My post was primarily directed to those recent investors who may not know all the history behind Hemodefend and how the results of this RECESS trial fit in.
There are quite a few major things that can land between now and year end. Good luck to you and all the other patient investors.
Just to set some expectations here, even the company has been working behind the scenes with a prospective partner for a Hemodefend licensing agreement, the publication of the results from this trial do not translate into a partnership announcement before year end. There are all the contractual aspects of such an agreement that will have to go through all the legal hoops before something tangible can be announced. With all the 'irons in the fire' they have between the uplisting, FDA talks, etc. between now and year end, I would think Q1 would be best case to see something with Hemodefend announced. I do agree that this is a significant catalyst that not only CTSO shareholders have been waiting for but also the other parties they have been in negotiations with.
Sentiment: Strong Buy
Nice!, thanks ping. Let's hope there are some evening meetings between them hashing out the licensing agreement once the results are presented ;)
At the end of July of this year, the Citizens for Responsibility and Ethics in Washington (CREW) has requested the Securities and Exchange Commission (SEC) investigate possible illegal manipulation of stock prices in several companies. Strategically released blog posts by well-known biotech stock analyst and senior columnist for TheStreet Adam Feuerstein seem designed to cause the price of a company’s stock to fall at times when short sellers were financially overexposed. CREW has asked the SEC and the U.S. Attorney for the Southern District of New York to conduct a full investigation of the timing of Mr. Feuerstein’s posts and their relationship to short seller financial interests. “When several drug companies repeatedly see big stock price dips due to a negative articles published at critical moments — especially when those dips benefit the financial interests of short sellers — it should raise serious questions at the SEC. Given the suspicious timing of Mr. Feuerstein’s articles, which include misinformation and innuendo, there should be an inquiry into whether there was a deliberate effort to manipulate the market for profit,” CREW Executive Director Melanie Sloan said.
jjgb - same here - are you talking about the article where the Citizens for Responsibility and Ethics in Washington (CREW) requested the Securities and Exchange Commission (SEC) investigate him on possible illegal manipulation of stock prices in several companies? Maybe I will try posting it without his name in it and see what happens.
Not sure whether he will remain on the board. Like most venture capital firms they don't go into an investment without an exit plan and are not usually invested for a long period - despite what the long term prospects of the investment may look like. This is from the NJTC Venture Fund profile:
"The firm invests between $250,000 and $5 million of capital over the course of a company's development, targeting companies seeking investment between $1 million and $10 million. It prefers to be a lead investor in its portfolio companies. The firm exits its investments between three years and seven years."
I think he and the firm came out pretty well on their investment wouldn't you say.
Go reach the last conference call transcript that is on the company's web site and all of your questions will be answered concerning Ebola and the filter. Below are a few excerpts:
"One of the key reasons why Ebola is so deadly is its ability to evade the immune system resulting in an advanced infection that triggers an overactive immune response, leading to organ failure. It does so by initially suppressing the antiviral cytokine immune response, which then allows robust viral replication. It also causes the production and release of soluble viral glycoproteins. These normally coat the surface of the virus but when they are soluble, they are free floating and can interfere with white blood cell activation and also act as decoys so that antibodies cannot neutralize the virus.
The scientific rationale behind using CytoSorb® in Ebola virus is that we may help patients by reducing "cytokine storm" primarily, but also by potentially removing soluble glycoproteins which are about 50 kDa in size, which is right in the size range that CytoSorb® can remove, thereby delaying the onset of fatal inflammation and organ failure while buying the patient time for the immune system to kill the virus.
Our strategy for outreach includes reaching out to many different organizations including the World Health Organization, the FDA, the CDC, as well as government agencies such as USAMRIID, non-profit organizations, and also hospitals treating Ebola patients inside and outside of West Africa, particularly those in Europe and the United States where patients with advanced infection have been (at least some of them) have been sent."
Ireland, I am right there with you and Z3 - I have felt this is the case for a while that the work that has been done under the SBIR contract with the NHLBI/NIH Funding in which they have worked on the platform itself, that in parallel they have been continuing the development of the HemoDefend™ In-line filter design and product specifications. This is substantiated by Chris Cramer's update on one of the conference calls:
We continue to be focused on developing our assets to a point that will make them attractive to outside partners. HemoDefend remains our primary development opportunity in the short term and we continue to make progress on this front. We are reviewing engineering proposals regarding tooling and filling equipment for commercial production of the HemoDefend in-line filter that is needed for regulatory approval, while we concurrently finalize development of the device."
I think that there is a partner in the wings they have been working with and the results of this very large trial (RECESS) will be the catalyst to bring that to the forefront. Hemodefend, even though it is technically still in development, has tremendous commercialization potential and I believe that you could see one or more types of licensing agreements or partnerships you laid out.
Sentiment: Strong Buy
Also check out Macopharma, Grifols and Cerus - these were also listed as potential partners in one of the last presentations.
CTSO also has a broader pipeline with Hemodefend already through product design and testing - awaiting an licensing deal with a large partner, once the ACCESS trial results are known later this month
Floyd, agree to your point but the public awareness of just having it as another tool to aid in the effort against Ebola deaths will be worth so much more. That is what I am hoping for.
Interesting that the quarterly results which they are forecasting was pre-released with a lot of other great updates. I believe that this might be the beginning of an organized news flow with other meaningful updates around the Q3 call in November including possible announcement of some type of partnership agreement, Ebola, etc.,- in order to begin to build some price momentum going into the RS. I seriously doubt they would have released this many updates without having other subsequent events lined up in the pipeline.
I have been investing for over 40 years and with today's press release jam packed with updates, have never seen a company with such a bright future.
Another outbreak for which there is applicability: Dengue Fever. While Ebola is getting all the headlines, China is dealing with "the worst outbreak in decades" of Dengue Fever. ITAR-TASS reports that the outbreak of the mosquito-borne disease in China has killed six people and infected more than 27,200 according to Chinese health officials. Just as of today the epidemic has infected 1,826 more people in the Guangdong Province alone and last month Malaysia reported that dengue fever deaths had more than tripled in 2014.
This is from the last conference call transcript:
"The International CytoSorb Registry will begin with two major patient groups: Severe Sepsis/Septic Shock and
Cardiac surgery patients. However, I expect that we will need to expand to other application fields rapidly since
there is a lot of interest and encouraging results in liver disease, burn and trauma patients, and other
applications. We even see interest in capturing treatment data for tropical diseases, such as Dengue fever and
malaria in India, and as Phil has described, MERS infections in many countries, particularly those in the Middle
He's been around for years under the angelajerkel, angelscousin and dr1_lowenstein #$%$. When there is not enough chatter on the board he dusts off one of these accounts and uses it to portend that there are multiple people with the same opinion. He's harmless.
Couldn't agree more tony. I can't wait to get out of this financial ghetto otherwise known as OTC market, and into the NASDAQ suburbs.
tony, this trial first surfaced on the board I believe back in early August by andy on 8/12. Here was ping's response regarding it and it may answer your question regarding the funding aspect:
"Nice find. Patients will be randomized into 3 groups, so approx 100 patients in each group. Seems the company doesn't have to pay for this as it is being sponsored by the university."